leadf
logo-loader
viewMidatech Pharma PLC
(
AIM:MTPH
)

Midatech Pharma's chief executive officer Dr Jim Phillips to step down at the end of May

Dr Phillips's successor as CEO will be COO Dr Craig Cook, who has more than 20 years of international experience in the pharmaceutical, biomedical and high technology sectors

Board room
There will be a transition period of around three months in order to ensure a smooth handover

Midatech Pharma Plc (LON:MTPH, NASDAQ:MTP), the pharmaceutical company focused on oncology and immunotherapy, said Dr Jim Phillips, is to step down as chief executive officer.

Having served the company for five years,  Philips will be succeeded at the end of May by Dr Craig Cook, who is currently the chief operating officer and head of research & development (R&D) at Midatech.

READ: Midatech Pharma shares jump as it wins orphan designation for liver cancer drug

Dr Steve Mamment, senior vice president of translational medicine, has been promoted to the head of R&D.

"I would like to thank Jim for his contribution over the last five years and wish him every success in his future endeavours. Under his dedicated leadership the company has transformed since 2013 from an academic entity to a publicly-funded, commercially-focused biotech company with strong prospects,” said Rolf Stahel, the non-executive chairman of Midatech.

“We are also fortunate that in Dr Cook we have an internal candidate who can take over responsibility as CEO, ensuring continuity and a controlled handover. Craig will provide strong leadership, demonstrated expertise, a deep understanding of the business, and a relentless focus on delivery of key value-driving programs to take Midatech into its next phase of growth. We have every confidence that Craig, together with his senior management team, will drive Midatech to a successful future," Stahel added.

Shares in Midatech fell a penny to 30p on the news.

 

Quick facts: Midatech Pharma PLC

Follow
AIM:MTPH

Price: 26.0604 GBX

Market Cap: £16.52 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Tiziana Life Sciences: A different approach, tackling disease using a safe,...

Tiziana Life Sciences (NASDAQ:TLSA) (LON:TILS)'s investment case is presented by Proactive Research Analyst John Savin who takes viewers through their activities and timeline of progress to come.  The firm deliver its fully human therapeutic antibody, foralumab, to the gut or nose mucosal...

27 minutes ago

2 min read